<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920203-0040</DOCNO><DOCID>920203-0040.</DOCID><HL>   Technology Brief -- Xoma Corp.:   Concern's Patent Is Upheld   Against Centocor's Claims</HL><DATE>02/03/92</DATE><SO>WALL STREET JOURNAL (J), PAGE B2</SO><CO>   CNTO XOMA</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>PATENTS (PAT)</NS><GV>JUSTICE DEPARTMENT (JUS)</GV><RE>CALIFORNIA (CA)NORTH AMERICA (NME)PENNSYLVANIA (PA)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   A federal court judge upheld Xoma Corp.'s patent supremacyover Centocor Inc. in their battle to develop antibodies forthe treatment of a lethal blood infection.   A U.S. District Court judge in San Francisco on Fridaydenied a motion by Centocor to set aside the verdict of ajury in October that Centocor had infringed the Xoma patent.In over-the-counter trading Friday, Xoma stock rose 75 centsto $24.25.</LP><TEXT>   Xoma, based in Berkeley, Calif., filed suit againstCentocor in April 1990 for infringement of its patentcovering the use of the antibodies targeted precisely againstendotoxin, a lethal poison released in the body during anoverwhelming bacterial blood infection known as gram-negativesepsis. About 400,000 people a year are believed to sufferfrom the condition.   As reported, in December, a judge ruled Centocor must makepayments to Xoma, but denied a hearing sought by Xoma to barCentocor from the market.   Despite its patent setback, Centocor's product Centoxinalready has received a recommendation of market approval by apanel of the Food and Drug Administration. Xoma's competingproduct, known as E5, has yet to get such a recommendation.   A spokesman for Centocor, Malvern, Pa., said the companyplans to appeal the case to the Court of Appeals for theFederal Circuit in Washington, D.C., once the District Courtjudgment is entered.</TEXT></DOC>